Cellectar Corp (CLRB) - Gross Profit Margin

Official company branding of Cellectar Biosciences Inc (CLRB)

Cellectar Biosciences develops precision radiopharmaceuticals to combat rare tumors. The gross margin as a percentage of revenue demonstrates the business's ability to protect profits, with the current level sitting around 0.00. Proprietary PDC conjugates ensure leadership in the therapy of macroglobulinemia. Stringent FDA requirements and isotope complexities create significant barriers to entry for new players in the sector.

CLRB (Cellectar Corp) Return on Gross Profit history from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for Cellectar Biosciences Inc (CLRB)

- market price and analyst price targets:
Basic company analysis:Cellectar Biosciences, Inc. (CLRB)
Manufactured products of Cellectar Biosciences, Inc.

Gross margin is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, allowing for an assessment of direct production efficiency. This metric reflects the ability of Cellectar Biosciences (CLRB) to monetize the unique radiopharmaceutical developments of highly qualified scientists, while gross margin variance captures the real-time assessment of the operating model's reaction to the cost of creating innovative drugs.